MEDIFAST INC is a personal services business based in the US. MEDIFAST shares (MED) are listed on the NYSE and all prices are listed in US Dollars. MEDIFAST employs 984 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $182.94 |
|---|---|
| 52-week range | $154.67 - $288.71 |
| 50-day moving average | $178.32 |
| 200-day moving average | $193.72 |
| Wall St. target price | $327.33 |
| PE ratio | 13.5445 |
| Dividend yield | $5.9 (3.66%) |
| Earnings per share (TTM) | $14.02 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $182.94 from 2022-06-29
| 1 week (2022-06-23) | -0.34% |
|---|---|
| 1 month (2022-05-28) | N/A |
| 3 months (2022-03-29) | 3.57% |
| 6 months (2021-12-31) | -12.65% |
| 1 year (2021-07-01) | -36.11% |
|---|---|
| 2 years (2020-07-01) | 29.50% |
| 3 years (2019-07-01) | 48.74% |
| 5 years (2017-06-30) | 341.14% |
Valuing MEDIFAST stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEDIFAST's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MEDIFAST's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, MEDIFAST shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
MEDIFAST's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.95. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEDIFAST's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
MEDIFAST's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $226.7 million.
The EBITDA is a measure of a MEDIFAST's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.6 billion |
|---|---|
| Operating margin TTM | 13.63% |
| Gross profit TTM | $1.1 billion |
| Return on assets TTM | 36.53% |
| Return on equity TTM | 84.29% |
| Profit margin | 10.28% |
| Book value | $18.77 |
| Market capitalisation | $2.2 billion |
TTM: trailing 12 months
Dividend payout ratio: 43.65% of net profits
Recently MEDIFAST has paid out, on average, around 43.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), MEDIFAST shareholders could enjoy a 3.66% return on their shares, in the form of dividend payments. In MEDIFAST's case, that would currently equate to about $5.9 per share.
While MEDIFAST's payout ratio might seem fairly standard, it's worth remembering that MEDIFAST may be investing much of the rest of its net profits in future growth.
MEDIFAST's most recent dividend payout was on 7 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 26 June 2022 (the "ex-dividend date").
Over the last 12 months, MEDIFAST's shares have ranged in value from as little as $154.67 up to $288.7061. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while MEDIFAST's is 1.3203. This would suggest that MEDIFAST's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Medifast, Inc. , through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
